Skip to content
Saturday, November 7, 2026
ModernBase

Giving Pluripotent Cells During Pregnancy to Babies with Neural Tube Defect Enhances Quality of Life, Study Reveals

An innovative research effort has revealed that delivering regenerative cells to fetuses suffering from spina bifida as part of a surgical repair could constitute a "significant breakthrough" in addressing congenital conditions.

Study Parameters and Security

The research conducted in the United States involved six unborn babies with the 'open' form of spina bifida. Surgeons applied regenerative cells sourced from the maternal placenta on the exposed area of the developing neural column during the repair procedure.

Significantly, the cell therapy proved to be secure. Doctors verified that the treatment did not lead to cancerous growths, interfere with wound healing, or block the correction of co-occurring hindbrain herniation.

Promising Outcomes

Magnetic resonance imaging performed on the newborns indicated a complete reversal of Chiari malformation in each of the babies. This favorable anatomical change is closely linked to better mobility and function.

"Should it enable additional babies able to walk who otherwise would not, it could establish itself as the new treatment paradigm," commented the principal investigator. "The results are profoundly encouraging and create a pathway toward a variety of prospective novel therapies."

Future Implications and Hope

Experts not involved in the trial proposed that additional validation of these observed advantages could announce a "different age" in prenatal intervention. The potential to improve nerve function impairment seen in utero is considered a revolutionary objective.

Notably important would be advancements for bladder and bowel function, which are frequent complications for individuals living with this disorder.

Future Directions

While this initial trial focused on a handful of cases, its established security and encouraging indicators provide a strong foundation for expanded clinical research. The addition of cellular treatment with current in-utero repair procedures offers substantial hope for transforming outcomes for babies yet to be born with this neural tube defect.

About the author

Erin Mcgrath

A tech strategist with over a decade of experience in digital innovation and startup consulting across Europe.

ModernBase

Type to search articles.